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INTRODUCTION
The immunization programme in Thailand, com-
menced in 1980, currently provides vaccines to 
protect against 10 childhood diseases, such as tu-
berculosis, hepatitis B, diphtheria, pertussis, teta-
nus, poliomyelitis, measles, mumps, rubella, and 
Japanese encephalitis, through scheduled EPI ses-
sions in hospitals and health centres around the 
country. The first dose of measles vaccination was 
incorporated into the national immunization pro-
gramme for children aged nine months in 1984. 
The second dose of measles vaccine was added in 
1996 for 1st grade students aged seven years. In 
1997, the second dose of measles vaccine was re-
placed by measles-mumps-rubella (MMR) vaccine. 
Rubella immunization was first provided to 6th 
grade female students aged 12 years during 1986-
1998 and, later, to 1st grade students of both the 
sexes during 1993-1996 before being replaced by 
MMR vaccine in 1997 as mentioned above (1). 
Ages in 2004 of the population under the measles 
and MMR immunization programme are provided 
in Table 1. Surveys indicated that the coverage of 
1st dose of measles vaccine was 48% in 1987, 82% 
in 1991, and above 90% since 1996. From the last 
survey, in 2003, the coverage of 1st dose of measles 
vaccine was 96% (2). The coverage of MMR vac-
cine among 1st grade students was 94% surveyed 
in 2004 (3).
As in other countries, the incidence of measles in 
Thailand has reduced dramatically since the intro-
duction of live measles vaccine into the routine 
immunization programme (4-6). The number of re-
ported measles cases reported in the National Dis-
ease Surveillance System has declined since 1984 
with an outbreak peak every 3-4 years, and mortality 
due to measles has become extremely rare (Fig. 1).   
The last peak years were 2001 and 2002 (11.8-16.5 
per 100,000 people) (6). The highest incidence was 
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observed in children who were too young for vac-
cination (7). Outbreaks of measles in children aged 
less than five years occurred exclusively in hard-to-
reach area where the coverage of vaccine was low. 
Nevertheless, outbreaks among urban and rural chil-
dren aged 7-15 years still occur occasionally.
In the case of rubella, MMR vaccine is adminis-
tered to school-age children aiming at preventing 
congenital rubella syndrome (CRS) and reducing 
morbidity. The incidence of rubella in Thailand is 
declining (Fig. 1), the reported rubella morbidity 
rate in 2003-2006 being only 0.61-0.78 per 100,000 
people (6). No outbreak of CRS has been noted in 
the last 10 years but the significance of this may 
be questionable as Thailand does not list CRS as a 
notifiable disease.
The purpose of mumps vaccination in Thailand is 
to reduce its associated complications and morbidi-
ty. The disease-surveillance data show high out- 
break peaks in 1995-1996 and, after that, the inci-
dence declined. During 2003-2006, the incidence 
of mumps was 12.2-17.6 per 100,000 people (6).
Although the epidemiological changes seen in the 
incidence of MMR in Thailand correspond well 
with immunization history and levels of coverage, 
the national immunization programme still needs 
to verify actual levels of immunity. Such informa-
tion would guide vaccination strategies in both 
preventing future outbreaks and pursuing the more 
ambitious targets of elimination or eradication. 
Accordingly, the main objective of this study was 
to review the seroprevalence of IgG antibodies to 
MMR among the Thai population after many years 
of vaccination against these diseases.
MATERIALS AND METHODS
The Ethical Committee for Research in Human Sub-
jects, Department of Disease Control, Nonthaburi, 
approved the study. There was no field serum speci-
men and evidence of data collection specifically for 
this study. The serum specimens were those remain-
ing from the 2004 hepatitis immunity study (de-
scribed below). Vaccination history was available only 
in relation to measles vaccination of children, aged 
less than five years, who had vaccination cards. 
Serum specimens
The sera used in the study were taken from 6,213 
Table 1. Age (in 2004) of Thai population sub-
ject to the measles, mumps and rubel-
la immunization programmes
Immunization Age (years) in 2004
Measles first dose* 1-20
Measles second dose† 7-15
Mumps† 7-14
Rubella† Female, 7-30
Male, 7-18
*Currently for children aged 9-12 months; 
†Currently in MMR for children aged 7 years; 
MMR=Measles, mumps, and rubella
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Fig. 1. Incidence of measles, mumps, and rubella, Thailand, 1973-2006 
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existing specimens remaining from a cross-section-
al descriptive study of hepatitis immunity in the 
Thai population in 2004 (8,9). The samples were 
collected from people in four provinces: Chiang 
Rai, Udon Thani, Chon Buri, and Nakhon Si Tham-
marat, having populations broadly representative 
of those in the northern, northeastern, central and 
southern regions respectively (Fig. 2). 
year(s) were re-categorized to demonstrate better 
the seroprevelance in age-group before and after the 
measles and MMR vaccination age of the child.    
Sera were collected and kept at -70 °C until tested. 
We used commercially-available ELISA IgG assays 
for measles (RE56611; IBL Immuno-biological Lab-
oratories, Hamburg, Germany), mumps (RE56641; 
IBL), and rubella (RE57081; IBL). The laboratory re-
sults were interpreted according to the instructions 
of each manufacturer, except for measles IgG. The 
positive cut-off point for mumps was at >12 U/mL, 
and for rubella, at >15 IU/mL.
For measles IgG, we calibrated the test using the 
National Substandard of Anti-Measles-Serum, Hu-
man, 1/92 (calibrated against the 1st International 
Standard Anti-Measles-Serum, Human 66/202) 
provided by the Robert Koch Institute, Berlin, Ger-
many. We set the positive cut-off point at 255 mIU/
mL (PRN titre=120) (10,11). The calibration was 
intended to translate the test results into interna-
tional units and to avoid the specificity of the test 
being too high. It indicated that the original cut-off 
point provided by the manufacturer was equiva-
lent to 601 mIU/mL. 
Analysis of data
Data were analyzed by determining the geometric 
mean titre for each viral IgG by age-group and the 
seroprotective rate (which is the proportion of speci- 
mens with antibody level about the cut-off point 
for each viral IgG) by age-group and by province. 
Chi-square test (p=0.05) was used for assessing the 
statistical significance of the differences between 
proportions. 
RESULTS
Measles IgG
In total, 1,092 serum specimens were tested for 
measles IgG. At a positive cut-off point of >255 
mIU/mL, 81% of the specimens (95% confidence 
interval [CI] 78.8-83.5) had protective antibody 
levels. The seroprotective rates for those aged be-
low 1, 1-7, 8-14, and 15-19 year(s) were 27%, 76%, 
73%, and 82% respectively, which were lower than 
expected. For the age-group of 20 years and above, 
the seroprotective rates were 91-96% (Table 2). The 
geometric mean titre (GMT) rose sharply in those 
aged 1-7 year(s) compared to those aged less than 
one year, but there was no increase in GMT in those 
aged 8-14 years compared to those aged 1-7 year(s) 
(Table 2). 
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Fig. 2. Map showing provinces from which 
serum samples originated
The participants were healthy children attending 
well baby clinics and healthy people with acute 
illnesses visiting outpatient clinics at the four pro-
vincial hospitals and two or three district hospitals 
in each participating province. The subjects had to 
meet the following criteria to include them in the 
study: be of good general health (apart from acute 
illness); have no chronic illness; not undergoing 
immunosuppressive therapy; and have no clini-
cal signs of infection with HIV or other immuno-
deficiency disorders. Sera were randomly sampled 
from the serum bank to provide a separate sample 
for MMR. The initial sample sizes were calculated 
to estimate the seroprevalence among each of 0-4, 
5-9, 10-14, 15-19, 20-24, 25-29, 30-39, 40-49, and 
50-59 year(s) age-group for each disease. However, 
in analysis, the age-groups of 0-4, 5-9, and 10-14 Tharmaphornpilas P et al. Immunity to measles, mumps, and rubella
Volume 27 | Number 1 | February 2009 83
Table 2. Geometric mean titre of IgG antibody and seroprotective rate against measles, mumps, and 
rubella, by age-group
Age 
(years)
Measles Mumps Rubella
Sample 
size
GMT (95% CI) 
(mIU/mL)
SPR (95% 
CI)  (%)
Sample 
size
GMT (95% 
CI) (U/mL)
SPR (95% 
CI) (%)
Sample 
size
GMT 
(95% CI) 
(IU/mL)
SPR (95% 
CI) (%)
0-7*
<1 year   
=34
<1 year=
21.0 
(8.7-50.4)
<1 year=
26.5
(13.5-44.7) 179
2.9
(1.7-5.1)
45.8
(38.4-53.4)
179
25.4
(20.7-31.0)
74.9 
(67.7-80.9) 1-7 
year(s) 
=338
1-7 year(s)=
412.1 
(334.0-508.5)
1-7 year(s)=
76.0
(71.1-80.4)
8-14 176 367.3
(293.2-460.2)
72.7
(65.4-79.0)
157 77.9
(56.6-107.2)
89.8
(83.7-93.9)
151 64.0
(54.9-74.7)
93.4
(87.8-96.6)
15-19 105 736.2
(560.1-967.7)
81.9
(72.9-88.5)
101 48.6
(28.3-83.7)
85.2
(76.4-91.2)
103 67.7
(58.9-77.8)
95.2
(88.5-98.2)
20-24 103 962.5
(776.4-1193.2)
93.2
(86.0-97.0)
89 87.8
(55.0-140.2)
91.0
(82.6-95.8)
  91 58.9
(46.3-75.0)
91.1
(82.9-95.9)
25-29   96 867.6
(691.0-1089.4)
90.6
(82.5-95.4)
94 55.8
(34.1-91.3)
86.2
(77.2-92.1)
  90 48.9
(37.7-63.5)
85.6
(76.2-91.8)
30-39   81 885.2
(743.3-1054.2)
92.6
(84.0-97.0)
98 86.3
(55.2-134.7)
90.8
(82.8-95.5)
  92 54.6
(42.8-69.6)
90.2
(81.8-95.2)
40-49   81 956.1
(818.2-1117.2)
96.3
(88.8-99.0)
95 120.4
(88.3-164.3)
94.7
(87.6-98.0)
  97 69.6
(62.2-77.8)
94.9
(87.8-98.1)
50+  78 851.5
(690.5-1050.0)
91.0
(81.8-96.0)
98 112.4
(80.2-158.2)
94.9
(87.9-98.1)
  96 65.1
(53.7-79.0)
96.9
(90.5-99.2)
*Separated to <1 and 1-7 year(s) for measles to reflect effect of vaccination at 9 months and 7 years; CI= 
Confidence interval; GMT=Geometric mean titre; SPR=Seroprotective rate 
Table 3. Number and percentage of children aged less than five years with documented measles vac-
cination having measles protective antibody
Region
 No. included in 
the study
No. with protective 
antibody 
Percentage (95% CI) 
with protective antibody 
Chiang Rai 45 39 86.7 (72.5-94.5)
Udon Thani 50 37 74.0 (59.4-84.9)
Chon Buri 21 15 71.4 (47.7-87.8)
Nakhon Si Thammarat 23 16 69.6 (47.0-85.9)
Total 139 107 77.0 (68.9-83.5)
CI= Confidence interval
Overall, the seroprotective rates of measles were 
similar (p=0.19) among provinces: Chiang Rai–
77.4%, Udon Thani–81.3%, Chon Buri–82.3%, and 
Nakhon Si Thammarat–84.4%. The seroprotective 
rates among females were higher than among 
males (85% vs 76%, p<0.001). Of 139 children aged 
less than five years with history of measles vaccina-
tion documented in a vaccination card, 77% had 
protective immunity (Table 3). Analyses by age, 
sex, and province among this group showed no sig-
nificant differences.
Rubella IgG
In total, 899 serum specimens were tested for rubella 
IgG. At a positive cut-off point of >15 IU/mL, 89% 
(95% CI 86.8-91.0) had protective antibody levels. 
The seroprotective rates were over 85% among 
children aged over seven years and among adults 
(Table 2). The GMT sharply increased at 8-14 years 
of age compared to the younger age-group (Table 
2). Of those who were aged 20-24 years and 25-29 
years, the seroprotective rates were higher among 
females than among males, but the differences 
(possibly reflecting rubella vaccination of 6th grade 
female students during 1986-1998) were not statis-
tically significant (96% vs 84%, p=0.14 and 89% 
vs 79%, p=0.34). The data indicate a higher sero-
protective rate in Chiang Rai (95.1%) than in other Tharmaphornpilas P et al. Immunity to measles, mumps, and rubella
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provinces (Udon Thani–85.5%, Chon Buri–88.3%, 
and Nakhon Si Thammarat–87.8%, p=0.007). 
Mumps IgG
In total, 911 serum specimens were tested for 
mumps IgG. At the positive cut-off point of >12 U/
mL in the testing manual, 82% (95% CI 78.9-84.0) 
had protective antibody levels. As with rubella IgG, 
the seroprotective rate was over 85% both among 
children aged seven years and above and among 
adults (Table 2). The GMT sharply increased at 8-
14 years of age compared to the younger age-group 
and seemed to be higher in the older age-groups 
(Table 2). The differences in seroprotective rates be-
tween males and females were not statistically sig-
nificant (80% vs 82%, p=0.66). The seroprotective 
rates were higher in Chiang Rai (89%) than in other 
provinces (Udon Thani–75.9%, Chon Buri–79.8% 
and Nakhon Si Thammarat–81.2%, p=0.001). 
DISCUSSION
Results of this study could reasonably be considered 
broadly representative of the Thai population but is 
probably not indicative of the situation of minority 
populations living in particular locations (e.g. the 
hill-tribes). The samples were collected from both 
urban and rural areas and from provinces in dif-
ferent parts of Thailand. This might be expected to 
introduce a bias towards urban populations hav-
ing better access to healthcare but, with regard to 
the immunization coverage, the major differences 
between urban population and rural population 
within the same provinces would not be expected.     
This study found that the immunity patterns of ru-
bella and mumps were as would be expected from 
the rubella and MMR vaccination in Thailand. 
The effects of MMR and the previous rubella vac-
cination programme (from 1986 to 1998, target-
ing 6th grade girls) was apparent in the age-group 
of 8-14 years and in women aged 20-30 years. The 
seroprotective rate of 46% for mumps and 75% of 
rubella among children below the age at which 
they would receive MMR vaccination suggests im-
munity acquired through continued transmission 
of wild virus in the community. To interrupt the 
transmission of virus in the future, MMR vaccine 
needs to be given to these younger children. 
Lowering the rubella IgG antibody cut-off point to 
10 IU/mL has been proposed, following epidemio-
logic evidence that the 10 IU/mL antibody level is 
protective in the vast majority of persons (12). Us-
ing this new cut-off point raised the overall sero-
protective rate of rubella from 89% to 93%. It also 
raised the seroprotective rate among children aged 
0-7 year(s) (children below the age of vaccination) 
from 75% to 83%, suggestive of increasingly severe 
transmission of wild virus among children before 
the vaccination age. 
The higher seroprotective rates for mumps and ru-
bella in the north compared to other regions were 
probably due to higher levels of virus transmission 
rather than a better vaccination programme. This 
conclusion reflects the finding that the higher sero-
protective rates persisted across all age-groups, i.e. 
were not specific to the age-groups covered by the 
immunization programme. For mumps, this find-
ing is consistent with the surveillance report show-
ing outbreaks of mumps in the north in 1990-1991 
and 1995-1996, peaking at 109.62 per 100,000 peo-
ple (13,14). However, the surveillance report sug-
gested that the incidence of rubella had been low 
in the north (especially in Chiang Rai where the 
incidence rate is 0.16-1.51 per 100,000 people) and 
in other regions throughout the last decade. These 
contradictory  findings  suggest  possible  under-
reporting of rubella and, perhaps, low awareness 
of the importance of detection of CRS.
The level of measles antibody found in this study 
raised concerns. One factor which may explain 
the apparently low positive rate was an ‘equivocal 
group’ having antibody levels of 150-254 mIU/mL. 
A measles seroepidemiology study, conducted in 
seven countries of Western Europe, found that the 
proportion of this equivocal group was high in the 
vaccinated age-groups, which is probably explained 
by lower antibody titre after vaccination (or more 
rapid antibody loss) than after natural infection (15). 
We found that 5.3% of our serum specimens fell 
in this equivocal group. The proportion of equivo-
cal cases among those aged less than 1, 1-7, 8-14 
and 15-19 year(s) were 2.9%, 6.5%, and 5.7% and 
4.8 respectively. The 77% positive and 6% equivo- 
cal rates among children, aged less than five years, 
who had documented a single dose of measles vac-
cine at 9-12 month, were in the acceptable range. 
Several hospital-based studies in Thailand found 
that almost 100% of infants had no antibodies to 
measles at nine months of age (16,17). After a sin-
gle dose of measles/MMR vaccine at nine months 
of age, 81-91% seroconversion rates (antibody 
level cut-off points 320 mIU/mL in 2 studies) were 
obtained (16-18), which are comparable with the 
results of studies in other developing countries (19-
21). However, the effectiveness of vaccine might 
vary as a result of field practice, which can be in the 
hands of relatively junior health officials. The ef-Tharmaphornpilas P et al. Immunity to measles, mumps, and rubella
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fectiveness of measles vaccine (when administered 
at nine months of age) was evaluated during seve-
ral outbreaks in Thailand, with varying results. In 
1994, for example, the effectiveness of vaccine was 
estimated to be 35-40% in a particular population 
living in a remote mountainous area (22). In 1995, 
it was estimated at 59-70% during one outbreak 
(23) but 85% in another (24). In 2002, one study re-
ported 91% (25) while another reported 87% (26).
Unexpectedly, a greater seroprotective rate or high-
er GMT for measles was not seen among children 
aged 8-14 years (supposed to have received the 
MMR vaccine at the age of 7 years) compared to 
those aged 1-7 year(s). We are unsure of the reasons 
for this but two hypothetical explanations seem to 
be plausible. The first, although not documented 
elsewhere, is a rapid waning of immunity after 
vaccination or secondary vaccine failure among 
school-age children. That is, immunity could have 
waned in children who were vaccinated but not 
subsequently exposed to circulating virus (27,28). 
The second possibility would be a potency prob-
lem with the measles component of MMR vaccine 
used in the programme. 
While some issues remain unresolved, the results 
of the present study do suggest explanations for 
Thailand continuing to have outbreaks of measles 
among school and college students. During 2006-
2007, there were nine outbreaks of measles reported 
to the National Epidemiology Office (29). Of these, 
five occurred among the minority populations 
with low vaccine coverage, i.e. hill-tribes, refugees, 
and displaced persons. Another four outbreaks oc-
curred among both urban and rural populations, 
with outbreak sizes ranging from three to 86 patients. 
The populations affected were secondary school 
students (86 and 7 persons) in two outbreaks, voca-
tional school students (46 persons) in one outbreak, 
and young adults (3 persons) in one outbreak. The 
high proportion of measles-susceptible school and 
college students means that Thailand may yet, at 
some point, have a nationwide outbreak. ‘Mop-up’ 
and ‘catch-up’ campaigns have reportedly been 
successful in raising the immune proportion of the 
population in many countries without major ad-
verse effects (30,31). It may be prudent to consider 
similar campaigns in Thailand before an explosive 
outbreak occurs.
Our conclusion is that, at the time of this study, the 
majority of the Thai population aged over seven 
years was immune to mumps and rubella. MMR 
immunization for the 1st grade students sharply 
reduced the number of susceptible children to 
mumps and rubella; however, a large proportion of 
younger children acquired the infection before the 
age of vaccination. To reduce the natural spreading 
of the diseases, MMR vaccination should be given 
to children at an earlier age. For measles, high sus-
ceptibility was found among children aged 8-14 
years. This finding was consistent with the age-
group reported as affected during outbreaks of mea-
sles in Thailand. Ineffectiveness towards measles of 
MMR immunization administered to the 1st grade 
students warrants further study. 
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